Literature DB >> 1464268

Epilepsy in Angelman syndrome associated with chromosome 15q deletion.

A Matsumoto1, T Kumagai, K Miura, S Miyazaki, C Hayakawa, T Yamanaka.   

Abstract

We report eight sporadic cases of typical Angelman syndrome (AS) associated with chromosome 15q12 deletion. Age at first visit was 3-35 months (average 18 months), and follow-up period was 4-20 years (average 14.1 years). The characteristic features of epilepsy in AS are (a) seizure onset in early childhood (8 of 8); (b) evolution of seizure type with age (8 of 8); (c) EEG abnormality changes from high-voltage slow bursts (HVS) in infancy to diffuse spike and waves in middle childhood (4 of 5); (d) atypical absence seizures (8 of 8), often occurring as atypical absence status (4 of 8); and (e) diminution of seizure discharges and clinical seizures after puberty (7 of 7). We believe that AS may frequently exist in the intractable epilepsies of childhood with severe mental retardation. We stress the importance of AS as one of the main etiologic background diseases of the intractable epilepsies with infantile onset such as West syndrome, Lennox-Gastaut syndrome, and others.

Entities:  

Mesh:

Year:  1992        PMID: 1464268     DOI: 10.1111/j.1528-1157.1992.tb01763.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

Review 1.  Angelman syndrome (AS, MIM 105830).

Authors:  Griet Van Buggenhout; Jean-Pierre Fryns
Journal:  Eur J Hum Genet       Date:  2009-05-20       Impact factor: 4.246

2.  Do the physiotherapy results make us happy in a case with 'happy puppet' (Angelman) syndrome?

Authors:  Ozgun Kaya Kara; Akmer Mutlu; Mintaze Kerem Gunel; Goknur Haliloglu
Journal:  BMJ Case Rep       Date:  2010-12-29

Review 3.  Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion.

Authors:  A Smith; C Wiles; E Haan; J McGill; G Wallace; J Dixon; R Selby; A Colley; R Marks; R J Trent
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

4.  A candidate model for Angelman syndrome in the mouse.

Authors:  B M Cattanach; J A Barr; C V Beechey; J Martin; J Noebels; J Jones
Journal:  Mamm Genome       Date:  1997-07       Impact factor: 2.957

5.  Parental view of epilepsy in Angelman syndrome: a questionnaire study.

Authors:  M Ruggieri; M A McShane
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

6.  Angelman syndrome in adulthood.

Authors:  Anna M Larson; Julianna E Shinnick; Elias A Shaaya; Elizabeth A Thiele; Ronald L Thibert
Journal:  Am J Med Genet A       Date:  2014-11-26       Impact factor: 2.802

Review 7.  Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms.

Authors:  Renzo Guerrini; Romeo Carrozzo; Roberta Rinaldi; Paolo Bonanni
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 8.  Epilepsy in patients with Angelman syndrome.

Authors:  Agata Fiumara; Annarita Pittalà; Mariadonatella Cocuzza; Giovanni Sorge
Journal:  Ital J Pediatr       Date:  2010-04-16       Impact factor: 2.638

Review 9.  Molecular mechanisms of antiseizure drug activity at GABAA receptors.

Authors:  L John Greenfield
Journal:  Seizure       Date:  2013-05-14       Impact factor: 3.184

10.  Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome.

Authors:  T M DeLorey; A Handforth; S G Anagnostaras; G E Homanics; B A Minassian; A Asatourian; M S Fanselow; A Delgado-Escueta; G D Ellison; R W Olsen
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.